Online inquiry

IVTScrip™ mRNA-Anti-KLKB1, DX-2930(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6872MR)

This product GTTS-WQ6872MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets KLKB1 gene. The antibody can be applied in Hereditary Angioedema (HAE) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000892.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3818
UniProt ID P03952
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-KLKB1, DX-2930(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ6872MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14304MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG-7221(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA RG-7221
GTTS-WQ10142MR IVTScrip™ mRNA-Anti-CGRP, LBR-101(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LBR-101
GTTS-WQ12526MR IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA NPVPDR001
GTTS-WQ15185MR IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA TA-650
GTTS-WQ15847MR IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA XmAb-18087
GTTS-WQ3507MR IVTScrip™ mRNA-Anti-APP, BAN-2401(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BAN-2401
GTTS-WQ12623MR IVTScrip™ mRNA-Anti-ERBB2, OMNITARG™(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA OMNITARG™
GTTS-WQ12142MR IVTScrip™ mRNA-Anti-CD248, MORAb-004(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MORAb-004
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW